ArticleCancer research communications2026
Breast Cancer-Protective Genetic Variant Common in Women of Indigenous American Genetic Ancestry Is a cis-eQTL for RMND1, ARMT1, and CCDC170 in HER2-Enriched Tumor Subtypes.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
Breast cancer genome-wide association studies in Hispanic/Latina women in the United States and Latin America have identified independent risk variants in the 6q25 region, including the protective variant rs140068132, located upstream of the estrogen receptor 1 (ESR1) gene. The molecular mechanisms linking this and other variants to breast cancer risk remain poorly understood. To investigate the potential functional role of rs140068132, we analyzed the association between this variant and gene expression in breast cancer tissue. We performed RNA sequencing on 270 tumors from the Peruvian Genomics of Breast Cancer Study and determined intrinsic tumor subtypes using PAM50. The effect of rs140068132 on gene expression across tumor subtypes was assessed using models adjusted for age at diagnosis, Indigenous American genetic ancestry, PAM50 subtype, and an interaction term between tumor subtype and SNP genotype. Subtype-specific effects of the protective rs140068132-G allele were observed in HER2-enriched tumors, with increased expression of ARMT1, RMND1, and CCDC170. These results suggest that in breast cancer tissue from Peruvian patients, rs140068132 influences the expression of multiple genes in a subtype-specific manner, likely acting through a regulatory element at 6q25 that modulates gene expression in cis depending on cellular context. SIGNIFICANCE: A protective germline variant, common in women of Indigenous American ancestry, upregulates the expression of cis-genes only in HER2-enriched tumors, providing valuable information for model selection in downstream mechanistic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.